国际患者水平汇总荟萃分析:氯胺酮输注治疗抑郁的临床调节因素探索
该研究汇总17项随机对照试验的个体患者数据(n=809),评估静脉氯胺酮对抑郁症状的快速抗抑郁效应及患者层面调节因素。结果显示氯胺酮在急性期(约24小时)和急性期后(约7天)均显著优于对照,效应在既往治疗抵抗较高(≥2种药物失败)和交叉设计的研究中更大,但未发现可指导个体化用药的患者层面特征。
要点
- 氯胺酮在急性期(约24小时)和急性期后(约7天)均显著改善抑郁症状。
- 研究水平调节因素:入组要求≥2种抗抑郁药失败和交叉设计的研究中效应更大。
- 未发现具有临床指导意义的患者层面临床或人口学调节因素。
核心结论
- 氯胺酮在异质性抑郁患者中稳健减轻抑郁症状,且对既往药物抵抗更强者相对安慰剂的获益更大。
- 未检测到可指导氯胺酮治疗决策的患者层面临床或人口学特征。
研究设计与样本
- 国际患者水平汇总荟萃分析,纳入17项静脉氯胺酮随机对照试验的个体患者数据,汇总n=809。
- 纳入标准要求相关精神科诊断、至少一个对照臂、不联用其他研究给药治疗,并使用MADRS或HRSD-17评估结局。
主要发现
- 氯胺酮对急性期(约24小时)抑郁严重度的主效应为β*=0.58(95%CI 0.44–0.72),p<0.0001。
- 氯胺酮对急性期后(约7天)抑郁严重度的主效应为β*=0.38(95%CI 0.23–0.54),p<0.0001。
- 研究水平调节因素显著:入组要求更高治疗抵抗(≥2种获批抗抑郁药失败)和交叉设计的研究中,氯胺酮相对安慰剂的效应更大。
- 数据驱动的组合调节因素分析仅发现统计学显著但幅度小且临床无信息价值的效果(效应量r≤0.29,小至中等效应)。
关键数值与推荐
- 33个候选调节因素在各研究中的患者层面数据可获得率为10.8%至100%(中位数55.6%)。
- 仅对至少40%数据集可用的调节因素进行序贯检验及数据驱动的组合调节因素分析。
临床怎么用
- 氯胺酮可考虑用于异质性抑郁患者,既往抗抑郁药治疗抵抗更明显者可能相对获益更大。
- 目前尚无患者层面特征可用于个体化选择氯胺酮治疗,临床决策仍需综合评估。
局限性
- 仅17/25项符合条件试验提供个体患者数据,部分调节因素数据可获得率低(最低10.8%)。
- 未检测到可指导临床决策的患者层面调节因素,组合调节因素效应小且临床无信息价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Depression is disabling and highly prevalent. Intravenous (IV) ketamine displays rapid-onset antidepressant properties, but little is known regarding which patients are most likely to benefit, limiting personalized prescriptions. We identified randomized controlled trials of IV ketamine that recruited individuals with a relevant psychiatric diagnosis (e.g., unipolar or bipolar depression; post-traumatic stress disorder), included one or more control arms, did not provide any other study-administered treatment in conjunction with ketamine (although clinically prescribed concurrent treatments were allowable), and assessed outcome using either the Montgomery-Åsberg Depression Rating Scale or the Hamilton Rating Scale for Depression (HRSD-17). Individual patient-level data for at least one outcome was obtained from 17 of 25 eligible trials [pooled n = 809]. Rates of participant-level data availability across 33 moderators that were solicited from these 17 studies ranged from 10.8% to 100% (median = 55.6%). After data harmonization, moderators available in at least 40% of the dataset were tested sequentially, as well as with a data-driven, combined moderator approach. Robust main effects of ketamine on acute [~24-hours; β*(95% CI) = 0.58 (0.44, 0.72); p < 0.0001] and post-acute [~7 days; β*(95% CI) = 0.38 (0.23, 0.54); p < 0.0001] depression severity were observed. Two study-level moderators emerged as significant: ketamine effects (relative to placebo) were larger in studies that required a higher degree of previous treatment resistance to federal regulatory agency-approved antidepressant medications (≥2 failed trials) for study entry; and in studies that used a crossover design. A comprehensive data-driven search for combined moderators identified statistically significant, but modest and clinically uninformative, effects (effect size r ≤ 0.29, a small-medium effect). Ketamine robustly reduces depressive symptoms in a heterogeneous range of patients, with benefit relative to placebo even greater in patients more resistant to prior medications. In this largest effort to date to apply precision medicine approaches to ketamine treatment, no clinical or demographic patient-level features were detected that could be used to guide ketamine treatment decisions.Review Registration: PROSPERO Identifier: CRD42021235630.
引用
- Price RB, Kissel N, Baumeister A, et al. International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators. Mol Psychiatry. 2022. PMID: 36071111. doi:10.1038/s41380-022-01757-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。